Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1001/jamaneurol.2014.463 http://scihub22266oqcxt.onion/10.1001/jamaneurol.2014.463 C4477824!4477824!24842754     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\24842754.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       JAMA+Neurol 2014 ; 71 (7): 896-900 Nephropedia Template TP {{tp|p=24842754|t=2014. Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody?Associated Encephalopathy |pdf=|usr=}}{{24842754}} gab.com Text Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody Associated Encephalopathy JO: JAMA Neurol http://www.kidney.de/pget.php?&tw=1&pmid=24842754 #FOAvip IMPORTANCE: This observational study describes the efficacy and safety of rituximab in 5 patients with voltage-gated potassium channel (VGKC)?complex/leucine-rich, glioma-inactivated 1 (LGI1) antibody?associated encephalopathy. Rituximab is a monoclonal antibody that targets CD20 and is used to treat other neurologic and nonneurologic diseases. OBSERVATIONS: This case series reports sequential seizure frequencies, modified Rankin Scale scores, and VGKC-complex antibody titers in 5 adult patients (median age, 65 years; range, 48?73 years) treated with rituximab. Median time from symptom onset to rituximab initiation was 414 days (range, 312?851 days). One patient showed a rapid clinical improvement after treatment with rituximab alone and experienced a rituximab-responsive clinical relapse. Another showed possible improvement on neuropsychometric memory indexes after rituximab therapy. In contrast, all patients showed robust responses to treatment with glucocorticoids, intravenous immunoglobulins, and/or plasma exchange at some point in their illness. Treatment with glucocorticoids?less so with intravenous immunoglobulins and plasma exchange?was associated with the most marked reductions in VGKC-complex antibodies. The only patient who did not receive glucocorticoids showed the poorest clinical and serologic responses. CONCLUSIONS AND RELEVANCE: Rituximab was well tolerated in this predominantly older adult patient population and may be an effective option for some patients with LGI1 antibody?associated encephalopathy. Glucocorticoid therapy appears particularly efficacious. Earlier rituximab administration and randomized trials are required to formally assess efficacy. Twit Text FOAVip Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody Associated Encephalopathy ????JAMA Neurol http://www.kidney.de/pget.php?&tw=1&pmid=24842754 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24842754 #FOAvip English Wikipedia <ref>{{Cite pmid|24842754}}</ref> Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody?Associated Encephalopathy #MMPMID24842754 Irani SR; Gelfand JM; Bettcher BM; Singhal NS; Geschwind MD JAMA Neurol 2014[Jul]; 71 (7): 896-900 PMID24842754show ga IMPORTANCE: This observational study describes the efficacy and safety of rituximab in 5 patients with voltage-gated potassium channel (VGKC)?complex/leucine-rich, glioma-inactivated 1 (LGI1) antibody?associated encephalopathy. Rituximab is a monoclonal antibody that targets CD20 and is used to treat other neurologic and nonneurologic diseases. OBSERVATIONS: This case series reports sequential seizure frequencies, modified Rankin Scale scores, and VGKC-complex antibody titers in 5 adult patients (median age, 65 years; range, 48?73 years) treated with rituximab. Median time from symptom onset to rituximab initiation was 414 days (range, 312?851 days). One patient showed a rapid clinical improvement after treatment with rituximab alone and experienced a rituximab-responsive clinical relapse. Another showed possible improvement on neuropsychometric memory indexes after rituximab therapy. In contrast, all patients showed robust responses to treatment with glucocorticoids, intravenous immunoglobulins, and/or plasma exchange at some point in their illness. Treatment with glucocorticoids?less so with intravenous immunoglobulins and plasma exchange?was associated with the most marked reductions in VGKC-complex antibodies. The only patient who did not receive glucocorticoids showed the poorest clinical and serologic responses. CONCLUSIONS AND RELEVANCE: Rituximab was well tolerated in this predominantly older adult patient population and may be an effective option for some patients with LGI1 antibody?associated encephalopathy. Glucocorticoid therapy appears particularly efficacious. Earlier rituximab administration and randomized trials are required to formally assess efficacy. äEffect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated (epmc).pdf DeepDyve Pubget Overpricing